NRG-CC010

Open to Accrual

Return to Protocol Table

A Phase III Trial of the Impact of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer

Principal Investigator

Edward Tanner, MD

Co-Principal Investigator(s)

Britt Erickson, MD

Status

Open to Accrual

Date Opened To Accrual

September 19 2022

Disease Site

Gynecologic [GY]

Uterine Corpus

Phase

III

Developmental Therapeutics

Primary Objective

To compare the rates of lower extremity limb dysfunction (defined as a ≥4-point increase in GCLQ symptom score from baseline) in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy.

Patient Population

Stage I endometrial cancer

Target Accrual

428

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Other

NRG-CC010 Study Overview by Edward Tanner, MD

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.